Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 4:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 1,605 matching trials from the live ClinicalTrials.gov search.
Conditions
Adrenocortical Carcinoma
Interventions
IL-13-PE
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Terminated Phase 1Phase 2 Interventional Results available

Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma

NCT00506779
Conditions
Uterine Cancer
Interventions
Imatinib Mesylate, Paclitaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
1
States / cities
Houston, Texas
Conditions
NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus, Squamous Cell Car. - Esophagus, Urothelial Carcinoma (UC), Bladder Cancer, Mesothelioma, Pleural Mesothelioma, Peritoneal Mesothelioma, Non-Small Cell Lung Cancer NSCLC, Pancreatic Cancer, Biliary Tract Carcinoma
Interventions
IDE892, IDE397
Drug
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
23
States / cities
Goodyear, Arizona • Phoenix, Arizona • Duarte, California + 19 more
Conditions
Prostate Cancer, Prostate Adenocarcinoma, Prostate Neoplasm, Prostate Cancer Metastatic, Castration-resistant Prostate Cancer
Interventions
Talazoparib, Temozolomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
9
States / cities
Basking Ridge, New Jersey • Montvale, New Jersey • Commack, New York + 6 more
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab Pegol, Placebo, Methotrexate
Biological · Other
Lead sponsor
UCB Pharma SA
Industry
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
70
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 63 more
Conditions
Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL)
Interventions
Ibrutinib, Copanlisib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Conditions
Metastatic Castrate Resistant Prostate Cancer
Interventions
Docetaxel, Radium 223
Drug · Radiation
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
4
States / cities
Boston, Massachusetts • Detroit, Michigan • Columbus, Ohio
Conditions
High Grade Glioma: Glioblastoma (GBM), High Grade Glioma: Gliosarcoma, Anaplastic Astrocytoma (AA), Anaplastic Oligodendroglioma (AO), Mixed Anaplastic Oligoastrocytoma (AOA)
Interventions
Plerixafor, Bevacizumab, Surgery
Drug · Procedure
Lead sponsor
Patrick Y. Wen, MD
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Leukemia
Interventions
Decitabine, Idarubicin, Cytarabine, Clofarabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 64 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Houston, Texas
Conditions
Multiple Myeloma
Interventions
Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
2
States / cities
Charlotte, North Carolina • Winston-Salem, North Carolina
Conditions
Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation
Interventions
BAY2927088_formulation A, BAY2927088_formulation B_1, BAY2927088_formulation B_2, BAY2927088_formulation B_3
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
11
States / cities
Gilbert, Arizona • Duarte, California • Atlanta, Georgia + 7 more
Conditions
Depression, Mild Cognitive Impairment
Interventions
Donepezil, Placebo, Citalopram, Venlafaxine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
55 Years to 95 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
New York, New York • Durham, North Carolina
Conditions
Pharmacokinetics of ASP9853, Non-hematologic Malignancies
Interventions
ASP9853, Docetaxel, Paclitaxel
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
4
States / cities
Boston, Massachusetts • Detroit, Michigan • Nashville, Tennessee
Conditions
Solid Tumors
Interventions
INCB057643, Gemcitabine, Paclitaxel, Rucaparib, Abiraterone, Ruxolitinib, Azacitidine
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • La Jolla, California • Denver, Colorado + 12 more
Completed Phase 1Phase 2 Interventional Results available

Azacitidine and CAPOX in Metastatic Colorectal Cancer

NCT01193517
Conditions
Colorectal Cancer
Interventions
Azacitidine, Capecitabine, Oxaliplatin, Azacitidine MTD
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Houston, Texas
Conditions
Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse, Pleiotropic Pathway Modifier, Glioblastoma, Lymphoma, Primary Central Nervous System Lymphoma
Interventions
CC-122
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
17
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 13 more
Conditions
Advanced Solid Tumor, Lymphoma
Interventions
GRC 54276, GRC 54276 + Pembrolizumab, GRC 54276 + Atezolizumab
Drug
Lead sponsor
Glenmark Specialty S.A.
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Huntersville, North Carolina • Milwaukee, Wisconsin
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Methoxyamine, Temozolomide
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Azacitidine, Magrolimab, Venetoclax
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Houston, Texas
Conditions
Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
Interventions
ONC-392, Pembrolizumab, Docetaxel
Drug
Lead sponsor
OncoC4, Inc.
Industry
Eligibility
18 Years and older
Enrollment
733 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
33
States / cities
Springdale, Arkansas • Davis, California • Downey, California + 27 more
Conditions
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions
CCI-779, Bevacizumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
2
States / cities
Rochester, Minnesota • Madison, Wisconsin
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
GTI-2040, gemcitabine hydrochloride, laboratory biomarker analysis, pharmacological study
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
oxaliplatin, leucovorin calcium, vorinostat, fluorouracil
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Interventions
Isotretinoin, Laboratory Biomarker Analysis, Pharmacological Study, Vorinostat
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 30 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
12
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more